Small Pharmaceuticals
Market Cap
₹2,094 ₹2,094 Cr.
P/E
24.49
PEG
2.27
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive if Pharmaceuticals segment revenue and consolidated EBITDA margin deliver the specified Q2 FY27 signals, validating the operating-growth and scale-benefit assumptions.

The bull path depends on Pharmaceuticals strength and sustained margin improvement, while the bear path reflects Pharmaceuticals weakness, consolidated margin pressure, or execution disruption during the leadership transition.

Key Ratios

Debt to Equity
Debt to Equity
0.00
Div Yield (%)
Div Yield (%)
0.45
Individual < 2 lac
Individual < 2 lac
38.39 %
Institutions
Institutions
0.35 %
Market cap
Market cap
2,094 Cr
No. of Shareholders
No. of Shareholders
4.22 L
OPM (%)
OPM (%)
17.64 %
PE
PE
24.49
Prom Holding
Prom Holding
50.57 %
ROCE (%)
ROCE (%)
23.77
ROE (%)
ROE (%)
18.42
Sales
Sales
497 Cr
  • Syncom Formulations
  • Panacea Biotec
  • Venus Remedies
Last updated on 1 Oct 2026
  • Syncom Formulations makes pharma formulations across tablets, capsules, injectables, liquids, ointments and inhalers. About 78% of sales are exports to over 15 countries.
  • Profit comes from own-made tablets. Injectables and traded tablets are growing. Other income is a third of pre-tax profit and moves with forex and subsidies.
  • It operates a WHO-GMP and ISO-certified plant. It sells 200-plus formulations. Management cites quality manufacturing and prescription-led marketing as its approach.
  • It is expanding injectable capacity with state incentives. Its sales mix is shifting from own-made tablets toward traded sourcing.
  • It is almost debt-free with growing property and treasury holdings. Higher raw-material stocks and tax balances are tying up working capital.
  • Near-term results depend on steady execution after the founder-to-family handover. The new managing director and whole-time director now lead with a new finance chief.
  • The founding family owns over half the shares. Many small holders own the rest.
  • First full quarter under new leaders On or before 14 Nov 2026
    It shows whether sales mix, costs and other income stay on track under new leadership.
  • State incentive receipts Next year to 2030
    They add to other income on receipt. Receipt depends on production and export conditions.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
10
52W Range
High
27
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Capex

Drug Delivery Break-Up

Raw Material Break-Up

Asset Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Syncom Formulations (India) Ltd. Business

Syncom Formulations (India) Ltd. specializes in manufacturing and marketing a wide range of pharmaceutical products in various dosage forms such as tablets, capsules, liquids, injectibles, and herbal products.

Syncom Formulations major competitors are Fredun Pharma, Beta Drugs, Panacea Biotec, Indoco Remedies, Venus Remedies, Sakar Healthcare, Jagsonpal Pharma.
Market Cap of Syncom Formulations is ₹2,253 Crs.
While the median market cap of its peers are ₹2,306 Crs.

Syncom Formulations seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Aug Sep
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material